Calidi Biotherapeutics Inc. (CLDI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Calidi Biotherapeutics Inc. (CLDI) has a cash flow conversion efficiency ratio of -1.342x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.04 Million) by net assets ($3.76 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see CLDI stock market capitalisation for the company's overall valuation and market capitalisation.
Calidi Biotherapeutics Inc. - Cash Flow Conversion Efficiency Trend (2020–2025)
This chart illustrates how Calidi Biotherapeutics Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Calidi Biotherapeutics Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Calidi Biotherapeutics Inc. ranked by their cash flow conversion efficiency. See CLDI operating cash to total liabilities to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CDN Maverick Capital Corp.
F:338B
|
-0.123x |
|
James Fisher and Sons PLC
LSE:FSJ
|
0.101x |
|
Omega Therapeutics Inc
NASDAQ:OMGA
|
-1.214x |
|
Dialight plc
LSE:DIA
|
0.300x |
|
FEEDBACK PLC LS-5
F:GZM0
|
N/A |
|
Traffic Technologies Ltd
AU:TTI
|
0.256x |
|
CPT Global Ltd
AU:CGO
|
-1.430x |
|
AMMPOWER CORP.
F:601A
|
-0.018x |
Annual Cash Flow Conversion Efficiency for Calidi Biotherapeutics Inc. (2020–2025)
The table below shows the annual cash flow conversion efficiency of Calidi Biotherapeutics Inc. from 2020 to 2025. View CLDI live share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $3.76 Million | $-21.29 Million | -5.665x | +43.39% |
| 2024-12-31 | $1.97 Million | $-19.69 Million | -10.007x | -405.41% |
| 2023-12-31 | $-8.23 Million | $-26.98 Million | 3.277x | +1150.74% |
| 2022-12-31 | $-50.44 Million | $-13.21 Million | 0.262x | -23.80% |
| 2021-12-31 | $-22.61 Million | $-7.77 Million | 0.344x | +60.15% |
| 2020-12-31 | $-22.48 Million | $-4.83 Million | 0.215x | -- |
About Calidi Biotherapeutics Inc.
Calidi Biotherapeutics, Inc., a biotechnology company, develops targeted therapies to deliver genetic medicines to distal sites of disease. The company offers CLD-101, which is in Phase 1b/2 clinical trial for the treatment of newly diagnosed high grade glioma, as well as in Phase 1 dose-escalation clinical trial for recurrent high-grade glioma; CLD-201 product for solid tumors, such as breast ca… Read more